Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
MMMK Development, Inc., a significant shareholder in Revolve Group , Inc. (NYSE:RVLV), recently executed a series of stock transactions, according to a Form 4 filing with the Securities and Exchange ...
Dozens of protesters voiced their anger at the proposed “decimation of the greenbelt” as councillors approved the final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback